Renal Program Advancing; Financing
November 8, 2016, Resverlogix presented at BIO Europe in Cologne, Germany.
Full set of 100 slides from Resverlogix R&D Update from 10/13/16 in NYC.
Maintaining CAD$5.00 Target: Awaiting First BETonMACE Futility Readout.
This Data in Brief article is a comprehensive presentation of the gene expression and protein analysis done in human whole blood and human primary hepatocytes.
Article in "Genetic Engineering & Biotechnology News" with a large focus on Resverlogix and Zenith
Here is the Checklist for Management from 7/28/16 that was composed by members of the RVX Agoracom Hub. We will do our best to update this list quarterly.